← Browse by Condition
Medical Condition
platinum resistant fallopian tube carcinoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for platinum resistant fallopian tube carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 1 1
Phase 2 2
Top Sponsors
1 trial
1 trial
Recruiting Clinical Trials
NCT05465941 Phase 2
Recruiting
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Enrollment
43 pts
Location
United States
Sponsor
Mayo Clinic
NCT05271318 Phase 1, Phase 2
Recruiting
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Enrollment
29 pts
Location
United States, Finla...
Sponsor
TILT Biotherapeutics Ltd.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology